$MET

MetLife and General Atlantic sidecar Chariot Re secures $700m in third capital raise

Chariot Re, a reinsurance sidecar by MetLife (MET) and General Atlantic, raised $700M in equity and debt. The capital will expand its life and annuity reinsurance platform. Chariot Re has raised over $2B since its 2025 launch, reinsuring $20B in liabilities. MetLife and General Atlantic cited strong business momentum and investor confidence.

Original reporting
Published Sep 2, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 2:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MetLife and General Atlantic sidecar Chariot Re secures $700m in third capital raise — source image
Decision brief

The 30-second read

$METBullishHigh
01

Why it matters

The $700 million raise expands Chariot Re's underwriting capacity, potentially boosting MetLife's long‑term earnings and market positioning in retirement solutions.

02

Market read

A sizable, first‑report capital raise for a MetLife‑affiliated reinsurance vehicle, likely to influence MET stock and the broader reinsurance sector.

03

What to watch

Execution risk of deploying the new capital efficiently and potential regulatory scrutiny.

Relevance 9/10Novelty 9/10Timing: today

Background

MetLife launched Chariot Re in July 2025 as a Bermuda‑based life and annuity reinsurance sidecar with General Atlantic.

Company-level read

Ticker impact

$METBullishHigh confidence
Context

MetLife's sidecar Chariot Re secured a $700 million capital raise, expanding its reinsurance capacity.

Expected impact

Potential modest upside for MET as investors price in higher future cash flows.

Evidence & confidence

Large, first‑report capital raise signals strong investor confidence and increased capacity for profitable reinsurance business.

Market effects

Reinsurance sector may see renewed interest as a major new capacity source emerges.

U.S. insurance market could benefit from expanded life annuity backing.

Signals confidence in global retirement solutions, potentially supporting broader financial services stocks.

Counterpoint

The raise could dilute existing equity and increase leverage, pressuring MET's valuation.

Key entities

  • MetLife, Inc.

    US‑listed insurer and sponsor of Chariot Re.

  • General Atlantic

    Private equity investor and co‑manager of Chariot Re.

Related articles

$METMedAI 8/10

METLIFE INC (MET): Regulation FD Disclosure

METLIFE INC (MET) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. MetLife, Inc. (the "Company") is furnishing this Current Report on Form 8-K to disclose preliminary information regarding variable investment income prior to the availability of the Company’s quarterly earnings release and quarterly financial s

$METMedAI 8/10

Is MetLife Outperforming the Nasdaq?

MetLife (MET) has outperformed the Nasdaq Composite, with shares up 22.5% year-to-date and 32.6% over 52 weeks. The company reported a 15.5% increase in adjusted earnings and 7% revenue growth in Q2 2026. Analysts have a 'Moderate Buy' rating with a mean price target of $106.23.

$METMedAI 8/10

MetLife (MET) Q2 2026 Earnings Call Transcript

MetLife (MET) Q2 2026 earnings call reported adjusted earnings of about $1.6 billion, or $2.43 per share, up 15% year over year. Adjusted premiums, fees and other revenues rose 5% (excluding pension risk transfers). Sales increased 7%, led by international growth. MetLife repurchased about $700 million of shares in the quarter and announced a new $3 billion authorization.

$METMed

MetLife Q2 Earnings Call Highlights

MetLife (NYSE:MET) reported Q2 expense ratio of 12.1%, up from 11.7% a year ago, citing a ~50 bps PineBridge Investments impact. Management said it is on track to beat its 12.1% full-year 2026 target. Group Benefits adjusted earnings rose to $503m, RIS to $377m, and MIM to $57m, with multiple segment margin and sales updates.

$METMed

MetLife reports $1.6bn adjusted earnings in second quarter 2026

MetLife reported second-quarter 2026 adjusted earnings of $1.6bn. Net investment income rose 18% to $6.7bn. Book value per share increased 8% to $38.59 and adjusted book value per share rose 3% to $57.71. The company returned over $1.1bn to shareholders via buybacks and dividends, and reported segment adjusted earnings gains across Group Benefits, Retirement and Income Solutions, Asia, EMEA, and MetLife Investment Management.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.